The @US_FDA approved the first treatment for Niemann-Pick disease type C. “We are immensely grateful for the unwavering support of the NPC community throughout this journey." said Neil F. McFarlane, President and CEO. Full announcement here: $ZVRA #NPC

.@Zevratx is a proud recipient of a 2025 WORLDSymposium New Treatment Award for the Company's product for the treatment of Niemann-Pick disease type C. #NPC #NiemannPick #RareDisease #NewTreatmentAward

.@Zevratx Day two recap from #WORLDSymposium in San Diego, CA! #TeamZevra has been forming meaningful connections engaging with the lysosomal disease community on the ground in San Diego, CA. Check out our posters: #LSDs #NPC

.@Zevratx is pleased to announce the acceptance of eight posters and one podium presentation highlighting the Company’s product for the treatment of Niemann-Pick disease type C at WORLDSymposium in San Diego, CA. For more: $ZVRA #WORLDSymposium #NPC

.@Zevratx will participate in upcoming investor conferences, including the Guggenheim Securities SMID Cap Biotechnology Conference and the @Oppenheimer & Co. Inc. 35th Annual Healthcare Life Sciences Conference. For more: #RareDiseases #Biotech #IR

.@Zevratx looks forward to connecting with those in San Francisco, CA, tomorrow through Wednesday during the J.P. Morgan Annual Healthcare Conference! $ZVRA #IR #BD

Zevra is proud to support the patients living with and caregivers impacted by #NiemannPick disease type C. Join us in hearing the Lazarus family's story about navigating the #NPC diagnostic and treatment journey with @IHTMPodcast.

.@Zevratx will be in San Francisco, CA, during J.P. Morgan’s 43rd Annual Healthcare Conference from January 13-16th. $ZVRA #IR #InvestorRelations #BusinessDevelopment

Wishing you a joyful holiday season and Happy New Year! #HappyHolidays #WeAreZevra

Answer: 45% to <85%

Zevra encourages you to gather information on the closest metabolic physician or hospital as you travel with your loved ones with #UreaCycleDisorders this holiday season. For more info to establish an emergency medical plan: $ZVRA #UCDs #RareDisease

Our Chief Medical Officer, Adrian Quartel, spoke with @KarenJagoda of Empowered Patient Podcast about a new treatment for #NiemannPick disease type C and how instrumental the #NPC community is in supporting #RareDisease treatment development. $ZVRA

Our Chief Executive Officer Neil F. McFarlane and Chief Commercial Officer, EVP Business Development Joshua Schafer spoke with @PharmaVoice about @zevratx's strategy for delivering therapies to patients with #RareDiseases. Learn more: $ZVRA #NPC #UCDs

.@Zevratx will be added to the @Nasdaq Biotechnology Index (Nasdaq: NBI) effective December 23, 2024. For more: $ZVRA #IR #InvestorRelations

Answer: 4.1 years

Vascular Ehlers Danlos Syndrome is a life-threatening #raredisease. Zevra is investigating celiprolol as a potential therapy for #VEDS.   Learn more about our DiSCOVER clinical trial and enroll here:  $ZVRA #RareDisease #ClinicalTrial

Neil F. McFarlane, President & CEO of Zevra will participate in the @Oppenheimer Movers in Rare Disease Summit at the Westin Grand Central in New York, NY, today. Looking forward to a great conference! $ZVRA #InvestorRelations #RareDisease

Zevra is committed to developing treatment for #raredisease. Our phase 3 clinical trial is evaluating the efficacy of our investigational drug celiprolol in treating #VEDS.   Learn more and enroll here: $ZVRA #ClinicalResearch #RareDisease

#DYK?: Holiday stress and changes in diet can trigger #hyperammonemia in people living with #UreaCycleDisorders. Be sure to know the signs of a #HyperammonemicCrisis for a safe, joyous holiday season: $ZVRA #UCDs #RareDisease